CTRI/2021/03/032039
Completed
Phase 2
Clinical study to evaluate the safety and efficacy of Darchini (cinnamomum zeylanicum Blume) in the management of non-alcoholic fatty liver disease.
Central council for research in Unani medicine New dehli0 sites60 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Sponsor
- Central council for research in Unani medicine New dehli
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •USG documented grade 1 and grade 2 non\-alcoholic fatty liver disease.
- •Patients with dull ache/ heaviness in the right hypochondriac region.
- •Patients with symptoms of dyspepsia and malaise.
- •BMI less than 34\.9kg/metre square.
- •Patients who are willing to give consent.
Exclusion Criteria
- •Alcoholic liver disease.
- •Grade 3 fatty liver disease and above.
- •Patients with cardiovascular and renal diseases.
- •Patients having focal fatty liver cirrhosis and known cases of hepatitis and other liver morbidities.
- •Patients having cholelithiasis and cholecystitis.
- •BMI greater than 34\.9kg/meter square.
- •Pregnant and lactating women.
- •Patients having endocrine disorders like diabetes mellitus.
- •Patients on lipid lowering drugs/statins.
- •Patients who fail to give consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
To study the effect of Tab HFO-O2 in fatty individuals.CTRI/2016/07/007067Baidyanath Bhavan Pvt Ltd
Recruiting
Phase 2
Clinical study to evaluate the safety and efficacy of Lunagel 2.5 dermal fillerIRCT20190210042676N33ikan Teb Kimia CO30
Active, Not Recruiting
Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of Livercure Tablets on Patients with Liver Cirrhosis.Health Condition 1: K745- Biliary cirrhosis, unspecifiedHealth Condition 2: K745- Biliary cirrhosis, unspecifiedCTRI/2022/07/043725Jammi Pharmaceuticals Pvt Ltd
Completed
Phase 2
A study for Under eye dark circlesCTRI/2022/09/045732Transformative Learning Solutions Pvt Ltd32
Active, Not Recruiting
N/A
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AEUCTR2005-003552-35-DEOctapharma AG116